Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.

British Journal of Clinical Pharmacology
F JiangJae-Gook Shin

Abstract

To evaluate the effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites in relation to the CYP2B6*6 genotype and explore potential phenotyping indices for CYP2B6 activity in vivo using a low dose of oral efavirenz. We conducted a randomized three phase crossover study in 17 healthy Korean subjects pre-genotyped for the CYP2B6*6 allele (CYP2B6*1/*1, n = 6; *1/*6, n = 6; *6/*6, n = 5). Subjects were pretreated with clopidogrel (75 mg day(-1) for 4 days), itraconazole (200 mg day(-1) for 6 days), or placebo and then given a single dose of efavirenz (200 mg). The plasma (0-120 h) and urine (0-24 h) concentrations of efavirenz and its metabolites (7- and 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz) were determined by LC/MS/MS. This study is the first to delineate quantitatively the full (phase I and II) metabolic profile of efavirenz and its three hydroxyl metabolites in humans. Clopidogrel pretreatment markedly decreased AUC(0,48 h), C(max) and Ae(0,24 h) for 8,14-dihydroxyefavirenz, compared with placebo; 95% CI of the ratios were 0.55, 0.73, 0.30, 0.45 and 0.25, 0.47, respectively. The 8,14-dihydroxyefavirenz : efavirenz AUC(0,120 h) ratio was significantly correlated with the weigh...Continue Reading

References

Aug 26, 1999·Drug Metabolism Reviews·S Ekins, S A Wrighton
Sep 30, 2003·Pharmacogenetics·Julia KirchheinerJürgen Brockmöller
Oct 11, 2003·The Journal of Pharmacology and Experimental Therapeutics·Vishal LambaErin G Schuetz
Oct 18, 2003·The Journal of Pharmacology and Experimental Therapeutics·Tanja RichterUlrich M Zanger
May 25, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Miia TurpeinenOlavi Pelkonen
Sep 24, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Joo-Youn ChoIn-Jin Jang
Jun 18, 2005·Clinical Pharmacology and Therapeutics·Miia TurpeinenKari Laine
Mar 1, 2006·European Journal of Clinical Pharmacology·Rajeev K MehlotraPeter A Zimmerman
Nov 15, 2006·Journal of Clinical Pharmacology·Robert L WalskyR Scott Obach
Jun 15, 2007·Pharmacogenomics·Zeruesenay DestaUlrich M Zanger
Jul 20, 2007·Pharmacogenomics·Ulrich M ZangerMatthias Schwab
Feb 22, 2008·Journal of Clinical Pharmacology·Evan D KharaschRebecka Coles
Feb 25, 2009·Pharmacogenetics and Genomics·Julia di IulioUNKNOWN Swiss HIV Cohort Study
Aug 26, 2009·Current Drug Metabolism·Sui-Lin MoShu-Feng Zhou
Nov 18, 2009·British Journal of Clinical Pharmacology·Jackson K MukonzoEleni Aklillu
Feb 16, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·S K BaeK-H Liu

❮ Previous
Next ❯

Citations

Jun 26, 2013·Current Cardiology Reports·Adam S FischAlan R Shuldiner
Aug 5, 2015·Journal of Clinical Pharmacology·David J Greenblatt
Oct 22, 2013·Journal of Clinical Pharmacology·A M AbdelhadyB R Overholser
Aug 9, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Yanxian HuLing Ye
Sep 30, 2017·Clinical Pharmacology and Therapeutics·Kimberly S BurgessTodd C Skaar
Sep 8, 2016·Antimicrobial Agents and Chemotherapy·Zeruesenay DestaRaymond E Galinsky
Jun 28, 2018·Pharmacological Reviews·Dhwanil A DalwadiJohn A Schetz
Aug 25, 2020·Expert Opinion on Drug Metabolism & Toxicology·Chang Hoon LeeDominick J Angiolillo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.